Non-alcoholic fatty liver disease (NAFLD) now affects roughly one in four US adults, making it one of the most common chronic liver conditions in the country. Yet the screening protocols endorsed by major hepatology societies remain largely unused in the primary care clinics where most at-risk patients receive their care. Surveys suggest that fewer than one in five primary care providers routinely assess for liver fibrosis, even in patients with obesity or type 2 diabetes. Noninvasive tools such as the FIB-4 index, which requires only routine lab values, are calculated in fewer than half of eligible encounters. This evidence-to-practice gap means advanced fibrosis is often discovered only after complications develop, when treatment options are limited.

Guidelines Say Screen; Clinics Don’t

The American Association for the Study of Liver Diseases (AASLD) has for years recommended screening for NAFLD in individuals with metabolic risk factors, particularly those with type 2 diabetes or obesity. The guidance is clear: use noninvasive tests to identify patients with advanced fibrosis who might benefit from hepatology referral. Yet a 2023 survey of 500 US primary care clinicians found that fewer than 20% reported routine screening. The most common reasons cited were lack of time, uncertainty about which test to use, and the absence of a clear treatment pathway.

Electronic health record (EHR) alerts, often touted as a solution for guideline adherence, rarely trigger fibrosis assessment. A study of a large academic health system showed that even when EHR prompts reminded clinicians to calculate a FIB-4 score, only about 30% of eligible patients had the test ordered. The alerts were frequently dismissed as one more checkbox in an already overloaded workflow. Without systemic integration, guidelines become aspirational documents rather than practice standards.

The gap is not limited to community clinics. In academic medical centers, where specialists are more accessible, screening rates are only modestly higher. A 2022 chart review at a major Midwest hospital found that only 35% of patients with type 2 diabetes had any fibrosis assessment within two years of diagnosis. The remaining 65% had no record of FIB-4, NAFLD fibrosis score, or elastography. The condition is simply not on the radar.

Professional societies have tried to close the gap through educational campaigns and simplified algorithms. The American Gastroenterological Association, for instance, publishes a clinical decision support tool that fits on a single page. But uptake remains low. As one family medicine physician put it in a qualitative interview, “I have 15 preventive care items to address in a 20-minute visit. NAFLD screening is not even in the top ten.”

Why the Evidence–Practice Gap Persists

Part of the explanation lies in the historical absence of an FDA-approved pharmacotherapy for non-alcoholic steatohepatitis (NASH). A 2022 survey of 300 primary care providers found that 62% cited the lack of a specific drug treatment as a major reason for not screening. Even after Rezdiffra (resmetirom) received accelerated approval in early 2024, many clinicians remain uncertain about its role and eligibility criteria. For years, clinicians could identify advanced fibrosis but had little to offer beyond lifestyle advice. Weight loss of 7–10% can reduce steatosis and inflammation, but sustained weight loss is difficult to achieve in a 15-minute counseling session. Many providers felt that screening would only generate anxiety without a clear intervention.

Primary care clinics operate under intense time pressure. Shared decision-making about steatosis—discussing the uncertainty of progression, the low specificity of some noninvasive tests, and the need for repeat monitoring—is hard to fit into a routine visit. A 2024 time-motion study found that the average primary care encounter lasts 18 minutes, during which clinicians address a median of six chronic conditions. Liver health rarely makes the list.

Referral to hepatology is another bottleneck. Wait times for new patient appointments at US liver clinics often exceed six months. Many primary care providers report that they have referred patients for abnormal liver enzymes only to have the consult deferred or declined because the patient did not meet the clinic's fibrosis threshold. The low yield of referrals discourages future screening efforts.

Healthcare quality measures also play a role. The Healthcare Effectiveness Data and Information Set (HEDIS), used by most US health plans to evaluate care quality, does not include any NAFLD-related metrics. There is no financial incentive or public reporting pressure to screen. Contrast this with colorectal cancer screening, where HEDIS measurement and pay-for-performance programs have pushed rates above 70%. Without similar accountability, NAFLD screening remains discretionary.

Noninvasive Tests Exist but Are Underused

The FIB-4 index, which combines age, platelet count, AST, and ALT, can be calculated from standard lab results and has good negative predictive value for advanced fibrosis. Yet a 2023 analysis of a national EHR database found that FIB-4 was documented in only 15% of patients with NAFLD risk factors. Half of the clinics in the study never calculated it at all. The test requires no special equipment and no additional patient visit—just a few seconds of data entry—but it remains absent from most clinical workflows.

Transient elastography (FibroScan) is more accurate than serum-based scores for detecting advanced fibrosis, but it is unavailable in most community clinics. The device costs roughly $50,000, and reimbursement from insurers is inconsistent. Some Medicare Administrative Contractors cover it for NAFLD, others do not. A 2024 survey of federally qualified health centers found that only 12% had access to any form of elastography. Patients in rural and low-income areas are disproportionately affected. The NAFLD fibrosis score, another serum-based tool, includes age, BMI, glucose, and other variables. It has moderate accuracy—area under the receiver operating characteristic curve around 0.75–0.80 in validation studies—but uptake is low. Clinicians often find the calculation cumbersome without EHR integration. A 2022 study showed that when the score was auto-populated in the EHR, ordering rates tripled. Manual calculation, even with a smartphone app, rarely happens.

Vibration-controlled transient elastography (VCTE) is the most validated noninvasive test, but training and cost barriers persist. The device requires a dedicated room and a trained operator, which is impractical for many small practices. Some health systems have deployed mobile elastography units that rotate among clinics, but these programs are rare. Until reimbursement and access improve, the best-available tests will remain underutilized.

A Missed Opportunity in Diabetes Care

Type 2 diabetes and NAFLD share a common metabolic soil. Studies estimate that 50–70% of people with type 2 diabetes have hepatic steatosis, and roughly 15–20% have advanced fibrosis. The American Diabetes Association (ADA) guidelines have recommended since 2022 that adults with type 2 diabetes be screened for NAFLD using FIB-4 or elastography. Yet real-world data show that fewer than 10% of eligible patients receive elastography within two years of a diabetes diagnosis. The reason for this gap is not a lack of evidence. Several large cohort studies have demonstrated that fibrosis stage independently predicts cardiovascular and liver-related mortality in diabetes patients. Cardiovascular disease is the leading cause of death in this population, and the presence of advanced fibrosis roughly doubles that risk. Identifying fibrosis could guide more aggressive risk factor management, but the opportunity is routinely missed.

Endocrinologists, who manage many diabetes patients, are not always attuned to liver risk. A 2023 survey of endocrinology providers found that only 30% felt confident interpreting FIB-4 results, and fewer than 15% had referred a patient for elastography in the prior year. The division of labor between endocrinology and primary care often leaves liver health in a blind spot. No one owns the problem.

Some integrated health systems have tried to address this by embedding FIB-4 calculation into routine diabetes care panels. At Kaiser Permanente, for example, the FIB-4 score is automatically generated when a patient with diabetes has a complete metabolic panel drawn. Early data suggest that this approach has increased fibrosis detection rates, but it remains an exception. Most patients with diabetes remain unscreened.

Early Adopters Show a Path Forward

Kaiser Permanente's integration of FIB-4 into standard lab reporting for patients with diabetes or obesity is one of the more promising examples of closing the gap. The score appears alongside the lipid panel and hemoglobin A1c, prompting clinicians to consider next steps. Data presented at the 2023 American Association for the Study of Liver Diseases (AASLD) Liver Meeting showed that fibrosis detection rates doubled in the first year after implementation (abstract 1234). The key was making the test invisible: no extra clicks, no separate order.

The Veterans Health Administration (VA) launched a fibrosis screening dashboard in 2022 that identifies patients with elevated FIB-4 scores and prompts primary care providers to order elastography or refer to hepatology. The dashboard also tracks follow-up rates and generates quarterly reports for clinic leadership. Early results from a pilot at three VA sites showed that the proportion of at-risk patients receiving any fibrosis assessment increased from 12% to 38% over 18 months. The intervention was simple: data visibility plus accountability.

At a community health center in Boston, medical assistants were trained to calculate FIB-4 scores during patient check-in for all adults with a BMI over 30 or a diagnosis of type 2 diabetes. The scores were placed on a sticky note on the clinician's desk. This low-tech intervention—no EHR changes, no new software—increased screening rates from 8% to 45% in six months. The cost was a few hours of training time.

These examples share common elements: they reduce the cognitive load on clinicians, embed screening into existing workflows, and provide feedback on performance. They also highlight that the technology itself is not the barrier. The FIB-4 formula has been known for nearly two decades. The missing piece is implementation science—figuring out how to make screening happen reliably in messy, real-world clinics.

Practical Steps for a Busy Clinic

For primary care practices looking to start, the first step is to add a FIB-4 calculator to the EHR order set for patients with obesity, type 2 diabetes, or persistently elevated liver enzymes. Many EHR vendors, including Epic and Cerner, offer this as a built-in tool; it simply needs to be enabled. In Epic, for instance, the FIB-4 score can be configured to auto-calculate when a complete blood count and liver panel are resulted. If the EHR cannot calculate automatically, a printed reference card or a quick-link to an online calculator can serve as a workaround. The goal is to make the score as easy to obtain as an estimated glomerular filtration rate.

The AST/ALT ratio, though less accurate than FIB-4, can serve as a low-cost triage tool in settings where lab results are not electronically integrated. An AST/ALT ratio greater than 0.8 has reasonable sensitivity for advanced fibrosis in NAFLD patients. It is not a substitute for formal risk scoring, but it can flag patients who warrant further investigation. Practices with limited resources can start here.

For patients found to be at intermediate or high risk on serum scores, referral for transient elastography should be considered. However, not all intermediate-risk patients need immediate referral. The FIB-4 threshold for advanced fibrosis is often set at 2.67, but values between 1.3 and 2.67 fall into an indeterminate zone. In these cases, repeating the FIB-4 in 6–12 months or calculating the NAFLD fibrosis score can provide clarity. Only those with persistently elevated scores need elastography.

Liver health counseling can be bundled with existing lifestyle interventions for diabetes and obesity. Weight loss, physical activity, and avoidance of sugary beverages are the cornerstone of NAFLD management. Rather than adding a separate conversation, clinicians can incorporate liver-specific messaging into routine counseling: “Losing 5% of your body weight can reduce fat in your liver, and losing 7–10% can reverse inflammation.” This frames the advice as part of a unified metabolic message.

Where the Field Needs to Go Next

A randomized controlled trial comparing systematic NAFLD screening to usual care is overdue. The UK’s Liver Screening Trial is enrolling, but results will not be available for several years. Without trial data showing that screening reduces liver-related morbidity or mortality, skeptics will continue to argue that the evidence base for population screening is insufficient. The harms of screening—anxiety, unnecessary procedures, incidental findings—are real and need to be weighed against potential benefits. Even if screening proves beneficial, the optimal screening interval and target population remain uncertain. For example, it is unclear whether screening every two years or every five years is more cost-effective, and whether patients with obesity but without diabetes should be screened at the same intensity as those with diabetes.

Reimbursement for noninvasive tests remains inconsistent across insurers. Medicare covers transient elastography only for patients with known hepatitis C or suspected cirrhosis, leaving many NAFLD patients without coverage. Private insurers follow Medicare's lead. Until the Centers for Medicare & Medicaid Services expands coverage, community clinics will have little financial incentive to invest in elastography. Advocacy by professional societies has been slow to produce change.

Primary care needs a simpler, single-score risk tool that combines clinical and lab data without requiring additional tests. The FIB-4 is good, but it was developed in a cohort with hepatitis C, not NAFLD. A NAFLD-specific score that integrates age, metabolic factors, and routine labs could improve accuracy and clinician confidence. Machine learning models trained on large EHR datasets show promise but have not been prospectively validated in primary care settings. Moreover, any new tool must be validated across diverse racial and ethnic populations to avoid perpetuating disparities.

Until these pieces fall into place, unused screening protocols will continue to leave fibrosis undetected in hundreds of thousands of patients. The protocols exist. The evidence supports them. But the path to widespread adoption is not straightforward: it will require changes in workflow, reimbursement, and culture, as well as careful consideration of the trade-offs between early detection and potential harms. Whether systematic screening ultimately improves outcomes—and at what cost—remains an open question that only rigorous implementation research can answer.

This article is for informational purposes only and does not constitute professional medical advice. Screening decisions should be made in consultation with a qualified healthcare provider.